Logo

BCC

Boise Cascade Company

BCC

Boise Cascade Company • NYSE
$76.24 ▲ 0.67% (+0.51)
Market Cap $2.82 B
52w High $149.99
52w Low $65.14
Dividend Yield 0.85%
P/E 15.04
Volume 232.31K
Outstanding Shares 37.04M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.668B ▼ $190.837M ▼ $21.769M ▼ 1.305% ▼ $0.582 ▼ $78.562M ▼
Q2-2025 $1.74B ▲ $218.125M ▲ $61.985M ▲ 3.562% ▲ $1.64 ▲ $124.16M ▲
Q1-2025 $1.536B ▼ $205.792M ▲ $40.348M ▼ 2.626% ▼ $1.06 ▼ $97.466M ▼
Q4-2024 $1.567B ▼ $204.992M ▼ $68.9M ▼ 4.396% ▼ $1.79 ▼ $136.857M ▼
Q3-2024 $1.714B $220.649M $91.038M 5.312% $2.34 $164.62M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $511.77M ▲ $3.402B ▼ $1.259B ▼ $2.143B ▼
Q2-2025 $481.019M ▼ $3.446B ▼ $1.293B ▼ $2.152B ▲
Q1-2025 $561.781M ▼ $3.482B ▲ $1.355B ▲ $2.127B ▼
Q4-2024 $713.26M ▼ $3.369B ▼ $1.218B ▼ $2.151B ▲
Q3-2024 $761.599M $3.442B $1.318B $2.123B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $21.769M ▼ $118.438M ▲ $-54.291M ▲ $-33.396M ▲ $30.751M ▲ $63.248M ▲
Q2-2025 $61.985M ▲ $33.17M ▲ $-69.88M ▼ $-44.052M ▲ $-80.762M ▲ $33.17M ▲
Q1-2025 $40.348M ▼ $-28.476M ▼ $-52.225M ▲ $-70.778M ▼ $-151.479M ▼ $-81.681M ▼
Q4-2024 $68.9M ▼ $94.568M ▼ $-97.676M ▼ $-45.231M ▲ $-48.339M ▲ $759K ▼
Q3-2024 $91.038M $174.587M $-63.477M $-271.587M $-160.477M $112.926M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Building Materials Distribution
Building Materials Distribution
 $1.44Bn ▲$1.41Bn ▼$1.61Bn ▲$1.56Bn ▼
Wood Products
Wood Products
 $420.00M ▲$130.00M ▼$450.00M ▲$400.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Boise Cascade’s revenue and profits have come down from the exceptional highs reached during the building boom a few years ago, but they remain clearly stronger than pre‑pandemic levels. Margins have narrowed as lumber and panel prices normalized and demand cooled somewhat, yet the company is still earning healthy operating and net income. Overall, the income statement shows a cyclical business that surged during peak housing and renovation activity and is now settling into more sustainable, but still solid, profitability.

Balance Sheet

Balance Sheet The balance sheet looks conservative and resilient. Total assets have steadily grown, supported by rising shareholder equity over time. Cash levels are robust relative to the size of the business, giving the company meaningful financial flexibility. Debt has stayed fairly stable and modest, which limits financial risk. In simple terms, Boise Cascade appears to be operating with a strong capital base, plenty of liquidity, and a manageable level of borrowing.

Cash Flow

Cash Flow Boise Cascade consistently generates positive cash flow from its operations, even as earnings have eased from peak levels. Free cash flow has been solid most years, after funding regular capital spending. Recently, the company has been increasing its investment in plants and equipment, which weighs somewhat on free cash flow in the short term but is aimed at supporting future growth. Overall, cash generation looks healthy enough to support ongoing investment and maintain a strong financial position.

Competitive Edge

Competitive Edge The company holds a strong competitive position in North American building materials, anchored by its combination of manufacturing and a broad distribution network. Its focus on engineered wood products, which offer performance advantages over traditional lumber, gives it a differentiated product mix. Vertical integration—producing wood products and distributing them through its own network—helps stabilize demand, improve cost control, and soften some of the swings that come with a cyclical construction market. However, Boise Cascade remains exposed to broader housing activity and wood price cycles, which can still create earnings volatility.

Innovation and R&D

Innovation and R&D Boise Cascade’s innovation is practical and very tied to its core products. It has developed specialized manufacturing techniques for engineered wood, as well as proprietary software and automated cutting systems that help builders design, plan, and use materials more efficiently. This combination of physical products and digital tools deepens customer relationships and creates switching costs. The company’s sizable planned investments in new and modernized facilities reflect a focus on upgrading technology, expanding engineered wood capacity, and strengthening its distribution network, rather than chasing entirely new product categories.

Summary

Boise Cascade today looks like a financially solid, vertically integrated building materials company that has moved off an unusually strong earnings peak and back toward more normalized conditions. Its strengths include a strong balance sheet, consistent cash generation, and a well‑entrenched position in engineered wood products and distribution. The main risks center on exposure to the construction cycle, lumber and panel price swings, and execution on a large slate of capital projects. On the opportunity side, continued adoption of engineered wood, ongoing network expansion, and technology‑driven services could support the company’s role as a key supplier to residential and light commercial construction over the long term.

NEWS

November 18, 2025 · 8:55 AM UTC

Boise Cascade Reaches Agreement to Purchase Holden Humphrey

Read more

November 17, 2025 · 7:30 AM UTC

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Read more

November 17, 2025 · 7:30 AM UTC

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Read more

November 13, 2025 · 7:30 AM UTC

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Read more

November 3, 2025 · 4:15 PM UTC

Boise Cascade Company Reports Third Quarter 2025 Results

Read more